Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

People with autism spectrum disorder (ASD) and intellectual disability (ID) often experience involuntary movements, which disrupt their ability to perform many tasks. A new device could help reduce ...

Adrian is the first paediatric patient with GNAO1 in Asia to undergo Deep Brain Stimulation surgery for this condition. SINGAPORE – Fewer than 500 people worldwide are known to have a rare genetic ...

When picturing signs of dementia to look for, the first ones that come to mind may be memory loss, struggling to think of the right word and having difficulty problem-solving. You may have also heard ...

The case description for a Case Records of the Massachusetts General Hospital appears below. What is the diagnosis? Cast your vote. The correct diagnosis, along with the full description of the case ...

Tardive dyskinesia (TD) is an involuntary neurological movement disorder that is usually a side effect of certain dopamine receptor blocking drugs. It mainly affects the face but can also cause ...

Tardive dyskinesia shares features with other movement disorders, such as Tourette syndrome and drug-induced Parkinsonism. But a diagnostic evaluation can reveal which condition is causing the ...

Parkinson's patients can suffer from a range of symptoms affecting their movement including something known as dyskinesia, which causes involuntary motion of body parts and makes everyday tasks a ...

Neurocrine Biosciences said on Monday its drug failed to meet the main goal in a late-stage clinical trial in patients with a type of disorder that disrupts the brain's ability to control muscles.

Kristin Weiland is a documentary film producer and writer with a background in crisis management and ethnographic research. She specializes in investigative and social impact documentary projects, and ...

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO ...